Achieve Life Sciences (QUIT) vs Trinity Biotech (TRIB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Achieve Life Sciences is the larger company by market cap ($573.2 million vs $5.1 million), about 113.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QUIT | TRIB |
|---|---|---|
| Share price | $5.56 | $6.24 |
| Market cap | $573.25M | $5.07M |
| 1-day change | -5.28% | +13.76% |
| EPS (TTM) | $-1.71 | $-60.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $61.55M |
| Revenue growth (YoY) | — | +8.31% |
| Net income (latest FY) | $-54.65M | $-31.79M |
| Gross margin | — | 34.83% |
| Operating margin | — | -34.38% |
| Net margin | — | -51.64% |
| 52-week high | $8.64 | $52.50 |
| 52-week low | $2.62 | $4.54 |
| Distance from 52-week high | -35.65% | -88.11% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +162.23% | — |
| Average volume | 1.38M | 13.54K |
| Shares outstanding | 103.10M | 813.13K |
| Employees | 28 | 287 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Achieve Life Sciences is about 113.0 times larger than Trinity Biotech by market value ($573.25M vs $5.07M).
About Achieve Life Sciences
QUIT stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About Trinity Biotech
TRIB stock →Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 287 employees
QUIT vs TRIB FAQ
Which is bigger, Achieve Life Sciences or Trinity Biotech?
Achieve Life Sciences (QUIT) is larger, with a market capitalization of $573.25M compared with $5.07M for Trinity Biotech (TRIB).
Are Achieve Life Sciences and Trinity Biotech in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.